by Market Overview:
The Middle East and Asia Pacific cell and gene therapy market involves developing innovative treatments to cure chronic diseases like cancer, neurological disorders, hematological diseases, and cardiovascular diseases. Cell and gene therapies help repair or replace dysfunctional cells and genes that lead to disease conditions. Some key application areas are cancer (CAR-T therapies), cardiovascular diseases (stem cell therapies), neurological disorders (gene editing therapies) and hematological diseases (gene therapies).
Market Dynamics:
The market is primarily driven by the high prevalence of chronic diseases, growing geriatric population, increasing adoption of advanced treatment options and favorable reimbursement policies in countries. According to WHO, cancer is one of the leading causes of mortality in countries like Japan, South Korea and China. Moreover, neurological disorders affect millions of people in India and other emerging economies. Thus, the demand for cell and gene therapies is anticipated to significantly rise in the coming years to treat chronic conditions more effectively.
Segment Analysis
The Middle East and Asia Pacific Cell And Gene Therapy Market Share is dominated by the oncology segment. Within this segment, CAR T-cell therapy is the leading sub-segment due to the approval and launch of Kymriah and Yescarta for the treatment of pediatric and young adult acute lymphoblastic leukemia as well as adult lymphoma.
PEST Analysis
Political: Developing standard regulations and guidelines for clinical trials and commercialization of cell and gene therapies by regulatory bodies in countries will boost the market growth.
Economic: Rising healthcare expenditure and disposable incomes in developing countries present lucrative opportunities.
Social: Growing awareness about advanced treatment options and improving access to healthcare will drive demand.
Technological: Ongoing research to develop new delivery mechanisms and targeted therapies is expected to enhance effectiveness.
Key Takeaways
The Middle East and Asia Pacific cell and gene therapy market is expected to witness high growth, exhibiting 17% CAGR over the forecast period, due to increasing prevalence of cancer and other chronic diseases.
Regional analysis: Within the region, China is expected to dominate the market due to high cancer burden, favorable reimbursement policies, and presence of leading market players. Countries like Japan, India and Australia are also lucrative markets.
Key players operating in the Middle East and Asia Pacific cell and gene therapy market are Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
